Evomela
Autoimmune Disease
Fred Hutchinson Cancer CenterPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
26 Active assets in the Autoimmune Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
total glucosides of paeony West China Hospital | Phase 4 | BB |
URSODEOXYCHOLIC ACID West China Hospital | Phase 4 | BB |
Cyclophosphamide The Children's Hospital of Zhejiang University School of Medicine | Phase 2 | B |
CEFADROXIL ANHYDROUS Mayo Clinic | Phase 4 | B |
Cephalexin Mayo Clinic | Phase 4 | B |
View all 35 →
Same molecule, other indications
Evomela is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →